As COVID-19 vaccine makers are working on omicron-specific shots, federal health authorities say there are signs they might not be necessary, writes Wall Street Journal.
However, research continues, officials say doses targeting the new variant might be needed longer-term, especially if it winds up crowding out earlier strains globally.
The U.S. omicron surge has triggered concerns that vaccines might need to be tweaked to specifically target the strain because existing shots don't appear to work as well against it.
Peter Marks, FDA's vaccine regulator, said. "By the time we get an omicron-specific vaccine manufactured, this wave will be over."
Dr. Marks said the next two months should show whether Omicron is likely to predominate over the long term, out-competing other strains.
Researchers also want to see how the immune responses generated by an omicron-targeted shot compare with those from original vaccines.
"We have strong evidence that, with a boost, current vaccines work well," said John Mascola, director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.
Also, earlier this week, a World Health Organization technical advisory group said that current vaccines might need to be updated to provide sufficient protection.
Photo by Gerd Altmann from Pixabay
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.